Showing results (111-120 of 124) with videos related to
Sort By:
Pageof 13
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.ESMO Open|August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II studyA Rodriguez-Vida, B P Valderrama, D Castellano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary GroupJ Bellmunt, V Guillem, L Paz-Ares, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2017
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)J Bellmunt, J M Kerst, F Vázquez, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-upA V Balar, D E Castellano, P Grivas, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.Urologic Oncology|June 4, 2018
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."M Y Teo, R M Bambury, E C Zabor, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2010
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) StudyJ Martin-Broto, A Gutierrez, X Garcia-Del-Muro, et al.Pageof 13